Acorai

Acorai announced today closed an oversubscribed seed equity funding round worth proceeds totaling more than $4.5 million.

Helsingborg, Sweden-based Acorai develops a first-of-its-kind device aimed to improve heart failure management. The non-invasive intracardiac pressure monitoring device aims to improve heart failure management. It received FDA breakthrough device designation in August following positive results from a 350-patient pilot study in Sweden.

The latest funding adds to a $2.5 million grant the company received in November. That grant featured a follow-on investment offer worth $10.7 million for the maximum funding amount.

Solardis Health Ventures led this latest funding round for Acorai. KHP Ventures, Carma Fund and other U.S. investors also participated. Acorai said it also received significant follow-on investment from existing investors in Sweden and across Europe.

The company already kicked off its CAPTURE-HF study and hopes to ha…

Acorai announced today that it received a $2.5 million (€2.3 million) grant to support its non-invasive intracardiac pressure monitoring system.

The European Innovation Council (EIC) selected Helsingborg, Sweden-based Acorai for the grant. It also features a follow-on investment offer worth $10.7 million (€10 million) for the maximum funding amount.

Acorai develops a first-of-its-kind device aimed to improve heart failure management. It received FDA breakthrough device designation in August after demonstrating promising results in a 350-patient pilot study in Sweden.

“Acorai’s receipt of funding from EIC clearly indicates the company’s potential to significantly impact both the health and economic fronts, not only in Europe but globally,” the company said in a news release. “The grant funding will support and help accelerate the progress toward the company’s goals, which are focused on clinical validation and regulator…